BRAF and melanoma: Nivolumab was granted FDA approval on December 22, 2014, for the treatment of individuals with metastatic or unresectable melanoma whose illness progressed even after ipilimumab therapy, and in patients who tested positive for a BRAF V600 mutation following treatment with a BRAF inhibitor (21).